Compare ADMA Biologics Inc (ADMA) vs Stanley Black & Decker, Inc. (SWK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Stanley Black & Decker, Inc. — how do they compare? ADMA Biologics Inc trades at $9.24 (market cap $2.13B), while Stanley Black & Decker, Inc. trades at $86.22 (market cap $13.89B). The key difference: Stanley Black & Decker, Inc. is far larger — about 6.5× ADMA Biologics Inc's market cap, and Stanley Black & Decker, Inc. pays a 3.71% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | SWK | |
|---|---|---|
Market Cap | $2.13B | $13.89B |
Sector | Health | — |
52-Week High | $20.38 | $94.12 |
52-Week Low | $7.60 | $62.12 |
Enterprise Value | $2.20B | $20.06B |
Dividend Yield | — | 3.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Stanley Black & Decker (SWK) trades at $89.37, down 2.75% today, with a bullish technical signal from moving averages but neutral oscillators. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 results pending. Revenue trends show stabilization around $15B annually, while net income improved to $401.9M in 2025. Debt reduction remains a priority, supported by positive operating cash flow of $971.2M.
SWK offers a turnaround story with improving profitability and shareholder returns via dividends, but faces headwinds from weak Tools & Outdoor demand and high debt levels. Analyst consensus is mixed with a $82.75 price target below current levels, suggesting cautious optimism amid execution risks and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →
